LABFF (Laboratorios Farmaceuticos Rovi) Debt-to-Asset : 0.12 (As of Mar. 2026)


LABFF Laboratorios Farmaceuticos Rovi SA LABFF
93 GF Score
Price $90.61
GF Value $82.42
! 1 Warning Sign
View Full Analysis

What is Laboratorios Farmaceuticos Rovi Debt-to-Asset?

Laboratorios Farmaceuticos Rovi LABFF 93 Debt-to-Asset is 0.12 as of Mar. 2026. GuruFocus rates LABFF with a GF Score™ of 93/100 and a GF Value™ of $82.42. The stock has 1 warning sign investors should review.

Laboratorios Farmaceuticos Rovi's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $32.1 Mil. Laboratorios Farmaceuticos Rovi's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $100.2 Mil. Laboratorios Farmaceuticos Rovi's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2026 was $1,070.9 Mil. Laboratorios Farmaceuticos Rovi's debt to asset for the quarter that ended in Mar. 2026 was 0.12.

Laboratorios Farmaceuticos Rovi  (OTCPK:LABFF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Laboratorios Farmaceuticos Rovi Debt-to-Asset Related Terms

Laboratorios Farmaceuticos Rovi Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Laboratorios Farmaceuticos Rovi's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Laboratorios Farmaceuticos Rovi Debt-to-Asset Chart

Laboratorios Farmaceuticos Rovi Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.10 0.08 0.08 0.14 0.13

Laboratorios Farmaceuticos Rovi Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.13 0.15 0.13 0.13 0.12

LABFF vs ZTS, UTHR, VTRS: Debt-to-Asset Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Laboratorios Farmaceuticos Rovi Debt-to-Asset vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Laboratorios Farmaceuticos Rovi's Debt-to-Asset falls into.


LABFF
93GF Score
Laboratorios Farmaceuticos Rovi SA LABFF
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Laboratorios Farmaceuticos Rovi Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Laboratorios Farmaceuticos Rovi's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(33.396 + 109.138) / 1119.076
=0.13

Laboratorios Farmaceuticos Rovi's Debt-to-Asset for the quarter that ended in Mar. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(32.105 + 100.194) / 1070.884
=0.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.12 mean?
Laboratorios Farmaceuticos Rovi (LABFF) has a Debt-to-Asset of 0.12 as of Mar. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Laboratorios Farmaceuticos Rovi and its competitors.
Is Laboratorios Farmaceuticos Rovi's Debt-to-Asset too high?
Laboratorios Farmaceuticos Rovi's current Debt-to-Asset is 0.12. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's Debt-to-Asset compare to ZTS and UTHR?
Laboratorios Farmaceuticos Rovi's Debt-to-Asset of 0.12 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Drug Manufacturers company?
A good Debt-to-Asset depends on the Drug Manufacturers industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. Laboratorios Farmaceuticos Rovi's current Debt-to-Asset is 0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Laboratorios Farmaceuticos Rovi (LABFF) has a current Debt-to-Asset of 0.12. The stock's GF Value™ is $82.42, compared to a current price of $90.61 — trading 9.9% above its estimated fair value. The current Debt-to-Asset is 0.12. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 93/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (LABFF), the current Debt-to-Asset is 0.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Laboratorios Farmaceuticos Rovi (LABFF) Overvalued in 2026?

Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued. The current stock price of $90.61 is trading 9.9% above its estimated GF Value™ of $82.42.

Key valuation signals for LABFF:

  • Debt-to-Asset: 0.12
  • GF Value™: $82.42 vs. price of $90.61 (9.9% above fair value)
  • GF Score™: 93/100 with 1 warning sign

No single metric tells the full story. See the LABFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Laboratorios Farmaceuticos Rovi Business Description

Address Julian Camarillo, 35, Madrid, ESP, 28037
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
93GF Score

Get the complete analysis for LABFF

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$90.61
Price
$82.42
GF Value